Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radi
The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected. The 129Xe tracer has not been FDA approved.
| Condition(s) | Lung Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected. The 129Xe tracer has not been FDA approved. Its use in this study is investigational. |
| Who can participate | Inclusion Criteria: 1. Healthy control cohort: 1. Able to consistently hold breath for 10-12 seconds 2. No history of any pulmonary disorders (i.e., asthma, COPD, lung cancer, etc.) 3. Able to undergo MRI examination 4. At least 18 years of age 2. Lung cancer patient cohort: 1. Biopsy proven diagnosis of lung cancer 2. Receiving photon- or proton-based external beam radiotherapy as a part of treatment 3. Able to undergo MRI examination 4. Will receive follow-up at University of Texas MD Anderson Cancer Center (UTMDACC) 5. Able to consistently hold breath for 10-12 seconds 6. Women and men with child-bearing potential agree to use adequate contraception prior to study entry and during the duration of study participation. 7. Able to understand and willing to sign a written informed consent d |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | M.D. Anderson Cancer Center |
| Locations | Houston, Texas, United States |
| Start date | 2026-03-31 |
| NCT ID | NCT06909201 |
| Official listing | https://clinicaltrials.gov/study/NCT06909201 |